PapersFlow Research Brief
Brain Metastases and Treatment
Research Guide
What is Brain Metastases and Treatment?
Brain metastases and treatment refers to the management of secondary tumors in the brain originating from extracranial primary cancers, primarily through surgical resection, radiosurgery, whole-brain radiation therapy, and prognostic stratification tools like recursive partitioning analysis.
The field encompasses 40,696 published works on brain metastases management, including radiosurgery and whole-brain radiation therapy. Key studies demonstrate that surgical resection followed by radiotherapy extends survival and improves neurological function compared to radiotherapy alone in patients with single brain metastases. Prognostic assessments, such as recursive partitioning analysis, classify patients into three classes based on Karnofsky performance status, age, primary tumor control, and extracranial disease status.
Topic Hierarchy
Research Sub-Topics
Stereotactic Radiosurgery for Brain Metastases
This sub-topic evaluates stereotactic radiosurgery (SRS) techniques like Gamma Knife for treating brain metastases, comparing outcomes with whole-brain radiotherapy. Researchers study local control rates, toxicity, and fractionation schedules.
Neurocognitive Effects of Brain Metastases Therapy
Studies assess declines in memory, executive function, and cognition post-radiotherapy or surgery for brain metastases. Interventions like memantine and hippocampal-sparing techniques are tested for preservation.
Prognostic Models for Brain Metastases
Researchers develop and validate indices like RPA, GPA, and DIAGNOSIS for predicting survival in brain metastases patients. Factors including primary tumor type, performance status, and extracranial disease are analyzed.
Blood-Brain Barrier Disruption in Metastases
This area investigates pharmacological and focused ultrasound methods to enhance drug delivery across the disrupted blood-brain barrier in brain metastases. Preclinical and clinical studies quantify permeability changes.
Immunotherapy in Brain Metastases Management
Research examines immune checkpoint inhibitors and combinations for brain metastases, addressing intracranial response rates and pseudoprogression. Trials focus on melanoma, NSCLC, and breast cancer subtypes.
Why It Matters
Brain metastases affect cancer patients by causing neurological deficits and reducing survival, with treatments like surgery plus radiotherapy offering concrete survival benefits over radiotherapy alone, as shown in Patchell et al. (1990) where the surgical group had a median survival of 40 weeks versus 15 weeks in the radiation group and reduced recurrence risk from 46% to 20%. Recursive partitioning analysis by Gaspar et al. (1997) enables risk-stratified therapy, defining Class 1 patients (KPS ≥70, age <65, controlled primary, no extracranial metastases) for optimized outcomes in radiation therapy trials. These approaches impact clinical decision-making in oncology, particularly for lung and breast cancer patients developing brain lesions, guiding personalized interventions to preserve cognitive function.
Reading Guide
Where to Start
"A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain" by Patchell et al. (1990), as it provides foundational evidence from a randomized trial showing surgery plus radiotherapy doubles median survival to 40 weeks over radiotherapy alone, establishing core principles for single metastasis management.
Key Papers Explained
Patchell et al. (1990) established surgery plus radiotherapy as superior for single brain metastases, with 40-week median survival versus 15 weeks. Gaspar et al. (1997) built on this by introducing recursive partitioning analysis from RTOG trials, stratifying patients into Classes 1-3 using KPS, age, primary control, and extracranial status for prognosis. Wen and Kesari (2008) contextualize malignant gliomas but relate to metastatic management through shared radiotherapy and temozolomide discussions, while Louis et al. (2016, 2021) update CNS tumor classifications informing metastasis pathology.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes immunotherapy roles, neurocognitive preservation post-radiosurgery, and HER2-positive breast cancer specifics, with focus on leptomeningeal metastasis challenges and blood-brain barrier effects, though no recent preprints are available.
Papers at a Glance
Frequently Asked Questions
What is the survival benefit of surgery plus radiotherapy for single brain metastases?
In a randomized trial, surgical resection followed by radiotherapy resulted in a median survival of 40 weeks compared to 15 weeks with radiotherapy alone. The surgery group also had a lower risk of death from neurological causes (19% vs. 50%) and reduced local recurrence (20% vs. 52%). Patchell et al. (1990) conducted this study in patients with single brain metastases from extracranial primaries.
How does recursive partitioning analysis classify brain metastases patients?
Recursive partitioning analysis defines three prognostic classes from RTOG trials: Class 1 includes patients with KPS ≥70, age <65, controlled primary tumor, and no extracranial metastases; Class 3 has KPS <70; Class 2 includes all others. This stratification predicts median survival differences across classes. Gaspar et al. (1997) developed these classes for homogeneous testing of new treatments.
What factors are considered in prognostic assessment for brain metastases?
Key factors include Karnofsky performance status (KPS), age, control of the primary tumor, and presence of extracranial metastases. Patients with KPS ≥70, age <65, controlled primary, and no extracranial disease form the best prognostic group. These derive from analysis of three Radiation Therapy Oncology Group brain metastases trials by Gaspar et al. (1997).
What treatments are used for brain metastases from extracranial cancers?
Treatments include surgical resection followed by radiotherapy for single metastases, whole-brain radiation therapy, and radiosurgery. Surgery plus radiotherapy improves survival and functional outcomes over biopsy plus radiotherapy. Patchell et al. (1990) demonstrated these benefits in a randomized trial.
Why is cognitive function important in brain metastases treatment?
Cognitive function impacts quality of life in brain metastases patients undergoing radiotherapy or surgery. Whole-brain radiation therapy and radiosurgery affect neurocognitive outcomes, requiring prognostic tools for treatment selection. The field addresses these effects alongside survival in management strategies.
What role does HER2-positive breast cancer play in brain metastases?
HER2-positive breast cancer frequently metastasizes to the brain, necessitating specific management considerations. Treatments target blood-brain barrier permeability and prognostic factors unique to this subtype. The topic cluster highlights these challenges in therapy development.
Open Research Questions
- ? How can treatments minimize neurocognitive decline while maximizing survival in patients with multiple brain metastases?
- ? What prognostic factors best predict outcomes in leptomeningeal metastasis from brain metastases?
- ? How does blood-brain barrier permeability influence immunotherapy efficacy for brain metastases?
- ? Which radiosurgery techniques optimize local control without increasing extracranial disease progression?
- ? How do molecular classifications of primary tumors refine brain metastases prognosis?
Recent Trends
The field maintains 40,696 works with emphasis on radiosurgery, whole-brain radiation therapy, cognitive impacts, and prognostic tools like Gaspar et al. 's classes; no growth rate data or recent preprints/news indicate steady incorporation of WHO CNS classifications from Louis et al. (2021) into metastasis pathology.
1997Research Brain Metastases and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Brain Metastases and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers